Guardian Financial Statements From 2010 to 2024
| GRDN Stock | 24.28 0.66 2.65% |
Check Guardian Pharmacy financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Guardian Pharmacy's main balance sheet or income statement drivers, such as , as well as many indicators such as . Guardian financial statements analysis is a perfect complement when working with Guardian Pharmacy Valuation or Volatility modules.
Guardian |
Guardian Pharmacy Services, Company Total Debt Analysis
Guardian Pharmacy's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Guardian Pharmacy Total Debt | 12.98 M |
Most of Guardian Pharmacy's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guardian Pharmacy Services, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Guardian Pharmacy Services, has a Total Debt of 12.98 M. This is 99.53% lower than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The total debt for all United States stocks is 99.76% higher than that of the company.
Guardian Pharmacy Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Guardian Pharmacy's current stock value. Our valuation model uses many indicators to compare Guardian Pharmacy value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Guardian Pharmacy competition to find correlations between indicators driving Guardian Pharmacy's intrinsic value. More Info.Guardian Pharmacy Services, is rated as one of the top companies in revenue category among its peers. It also is one of the top stocks in net income category among its peers making up about 0.02 of Net Income per Revenue. The ratio of Revenue to Net Income for Guardian Pharmacy Services, is roughly 43.77 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Guardian Pharmacy's earnings, one of the primary drivers of an investment's value.About Guardian Pharmacy Financial Statements
Guardian Pharmacy investors utilize fundamental indicators, such as revenue or net income, to predict how Guardian Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Pair Trading with Guardian Pharmacy
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Guardian Pharmacy position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guardian Pharmacy will appreciate offsetting losses from the drop in the long position's value.Moving against Guardian Stock
| 0.75 | NVOS | Novo Integrated Sciences | PairCorr |
| 0.43 | TOI | Oncology Institute | PairCorr |
| 0.41 | TOIIW | The Oncology Institute | PairCorr |
| 0.4 | NIVF | NewGenIvf Group | PairCorr |
| 0.39 | PACS | PACS Group, | PairCorr |
The ability to find closely correlated positions to Guardian Pharmacy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Guardian Pharmacy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Guardian Pharmacy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Guardian Pharmacy Services, to buy it.
The correlation of Guardian Pharmacy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Guardian Pharmacy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Guardian Pharmacy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Guardian Pharmacy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Guardian Pharmacy Correlation against competitors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardian Pharmacy. If investors know Guardian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardian Pharmacy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Guardian Pharmacy is measured differently than its book value, which is the value of Guardian that is recorded on the company's balance sheet. Investors also form their own opinion of Guardian Pharmacy's value that differs from its market value or its book value, called intrinsic value, which is Guardian Pharmacy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardian Pharmacy's market value can be influenced by many factors that don't directly affect Guardian Pharmacy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardian Pharmacy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.